- Dec 13, 2018
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
IFM 2018-04 NCT03606577: Phase 2: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell...
497
- Dec 6, 2018
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation...
218
- Dec 22, 2017
Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone
Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review...
24
- Dec 14, 2017
NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Myeloma NDMM
Multiple Myeloma Research Consortium NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple...
44
- Dec 7, 2017
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...
66
- Dec 6, 2017
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
MUKnineb Study OPTIMUM To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab...
482